This article is more than 5 years old. Information may no longer be current.

Kala Pharmaceuticals raises $11.5 million to advance ophthalmic programs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Kala Pharmaceuticals has secured $11.5 million in Series A equity financing to help move two of its ophthalmic platforms through clinical proof of concept, according to a company news release.

Kala focuses on products designed to penetrate the mucosal barrier to treat a variety of diseases. This funding will help advance programs focused on topical treatment of ocular inflammation and wet age-related macular degeneration, the release said.

The funding comes from Crown Venture Fund, Lux Capital Management, Polaris Venture Partners and Third Rock Ventures, according to the release.